Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases

NCT ID: NCT05195710

Last Updated: 2025-11-10

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 50 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-11-16
• Study Completion Date: 2026-03-31

Brief Summary

A prospective, interventional study evaluating the safety of Y-90 TARE for tumor control of the right side and induction of left liver hypertrophy as part of a planned single-stage or two-stage hepatectomy for patients with CLM and insufficient FLR at the time of presentation.

Detailed Description

Primary Objective:

To examine the safety and feasibility of Y-90 TARE directed to the right hemi-liver for induction of left liver FLR hypertrophy as part of a planned hepatectomy for patients with CLM.

Secondary Objectives:

• To describe changes in liver volume after Y-90 TARE, including:

• The kinetic growth rate (KGR) of the FLR
• Degree of hypertrophy 6 weeks after TARE
• Atrophy of targeted right hemi-liver from TARE date to date of surgery
• To describe additional interventional procedures needed to induce additional hypertrophy if insufficient hypertrophy from Y-90 TARE
• To assess the proportion of TARE patients who undergo attempted and complete curative-intent resection of CLM
• To assess measures of disease control, including:

• Tumor marker trend
• RECIST/mRECIST criteria
• CT morphologic response
• PET CT response
• To describe Patient Reported Outcomes using MDASI-GI
• To assess FLR liver quality, right-sided surgical adhesions from TARE intraoperatively
• To describe dosimetry of individual liver lesions - using SPECT/CT, CT, and pathology correlation
• To describe change in liver function measured by the pre- and post-TARE HIDA SPECT/CT scans and hepatic function blood tests

Conditions

Metastases

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Yttrium-90

Help to control the tumor(s) on the right side of the liver while the remaining left side of the liver, which is clear of cancer, grows.

Group Type: EXPERIMENTAL

Yttrium-90 (Y-90) resin microspheres

Intervention Type: DRUG

Given by scan

Interventions

Yttrium-90 (Y-90) resin microspheres

Given by scan

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Borderline resectable unresectable (due to insufficient liver volume at presentation) colorectal liver metastases with potential curative intent, as determined by the surgeon and multidisciplinary team
• Anticipated standardized FLR (sFLR) that would require right portal vein embolization (PVE) to increase the sFLR prior to either a single major hepatectomy, or prior to the second stage hepatectomy as part of a two-stage hepatectomy strategy, all in the setting of curative-intent resection(s). This evaluation will be documented in the clinical chart
• Received at least four cycles (or two months) of chemotherapy
• Willing, able and mentally competent to provide written informed consent
• Medically and physically operable as determined by the surgeon

Exclusion Criteria

• Extrahepatic disease that precludes intended curative intent treatment sequencing (treatable primary tumor and lung metastases allowed). "Treatable" is defined as having an intended future plan for local therapy (surgery, radiation, or ablation) as determined by the patient's medical oncologist and surgical oncologist
• Projected sFLR before Y-90 of <20% (starting with sFLR that is unrealistic for improvement to ≥30%)
• Performance status limitations (Karnofsky <80%, ECOG >1)
• Portal hypertension and/or cirrhosis
• Starting total bilirubin >1.3 mg/dL (except if patient has Gilbert's Disease)
• CEA >200 after 4 cycles of chemotherapy upon restaging visit
• Clinical progression of disease on imaging and/or tumor marker after 4 cycles of chemotherapy that is clinically judged by surgical oncology and medical oncology to preclude surgical resection
• Platelet count <100,000/µL
• Albumin <3.5 g/dl
• Symptomatic primary colon or rectal cancer (without pre-existing proximal diverting ostomy)
• Pregnant or breast-feeding patient
• Other medical or clinical contraindications to liver surgery
• Non-English-speaking participants

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sirtex Medical

INDUSTRY

Sponsor Role: collaborator

M.D. Anderson Cancer Center

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ching-Wei Tzeng, MD

Role: PRINCIPAL_INVESTIGATOR

M.D. Anderson Cancer Center

Locations

M D Anderson Cancer Center

Houston, Texas, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Ching-Wei Tzeng, MD

Role: CONTACT

Phone: (713) 792-0386

Email: cdtzeng@mdanderson.org

Facility Contacts

Ching-Wei David Tzeng, MD

Role: primary

Related Links

http://www.mdanderson.org

M D Anderson Cancer Center

Other Identifiers

NCI-2021-13239

Identifier Type: OTHER

Identifier Source: secondary_id

2021-0521

Identifier Type: -

Identifier Source: org_study_id